Stockreport

Gilead Sciences to Acquire Arcellx to Maximize Long-Term Potential of Anito-cel

Gilead Sciences, Inc.  (GILD) 
Last gilead sciences, inc. earnings: 4/30 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.gilead.com
PDF – Builds on Successful 2022 Collaboration on Anito-cel, a Potentially Transformative Treatment for Patients with Multiple Myeloma –– FDA Accepted Anito-cel BLA for the T [Read more]